Equity Profile

AZN

AstraZeneca PLC

Health CarePharmaceuticals$262.8B

Feb10Tue

Pre-Earnings Brief

UpcomingQ1-2018Pre-Market9:00 AM EST

Company Snapshot

AstraZeneca PLC (AZN) is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Operating in the health care sector, AstraZeneca is known for its innovative treatments in areas such as oncology, cardiovascular, and respiratory diseases, making it a significant player in the pharmaceuticals industry.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AZN Q1-2018 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+72.85%

Avg Stock Reaction

-1.24%

Last Quarter Recap

In the last quarter, AstraZeneca reported an impressive EPS of $1.30, beating estimates by over 66%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continue to advance the product pipeline in oncology and respiratory treatments.
Focus on expanding market access for existing drugs.
Commit to maintaining strong research and development investments.

Expectations

Wall Street Expectations

Overall, expectations are mixed as AstraZeneca prepares for its upcoming earnings report. Investors are eager to see if the company can maintain its trend of beating EPS estimates.

Bull Case

If AstraZeneca reports strong earnings and provides positive updates on its product pipeline, it could lead to increased investor confidence and a potential stock price rally.

Bear Case

Conversely, if the company misses expectations or fails to provide clear guidance on future growth, it could lead to a sell-off as investors reassess their positions.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated guidance for EPS and revenue growth for the upcoming quarters?

Clear guidance will help investors understand the company's trajectory and growth potential, influencing stock performance.

How is the product pipeline progressing, especially for key drugs in development?

Updates on the product pipeline can significantly impact future revenue and investor sentiment, making this a critical area of focus.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating AstraZeneca's ability to leverage its strong product pipeline, particularly in oncology, which could lead to higher-than-expected revenue growth.

Supporting Evidence

AstraZeneca has a track record of exceeding EPS estimates, with an 86% beat rate over the last eight quarters.

The options market is pricing a move that aligns with historical averages, suggesting that traders are not fully accounting for potential upside.

Recent product launches have shown strong market acceptance, which could drive revenue higher than anticipated.

Key Risk

If the product pipeline shows significant advancements or unexpected approvals, it could lead to a positive reassessment of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings will be pivotal in determining whether AstraZeneca can sustain its growth momentum in a competitive market.

Bull Confirmed If

AstraZeneca reports EPS growth exceeding 20% year-over-year, indicating strong operational performance.

Bear Confirmed If

A significant decline in EPS or lack of clarity on the product pipeline could signal trouble ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±4.3%

Historical Avg

±4.2%

In line with history

The options market is pricing in a potential move of about 4.3% following the earnings report, indicating that traders expect some volatility.

Options pricing is consistent with the historical average move of the stock around earnings.

Detail

ATM IV

0.3%

30d HV

20.7%

Calls (35K)P/C Ratio: 1.14Puts (91K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AstraZeneca beats expectations, history suggests a potential stock increase of around 1% on the first day, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary from management.

Miss

Should the company miss expectations, history indicates a potential decline of about 1% on the first day, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of key drugs in the pipeline, particularly in oncology.
2Guidance on revenue growth expectations for the upcoming quarters.
3Insights into market share changes in key therapeutic areas.
4Discussion of any challenges faced in the regulatory approval process.
5Management's outlook on competitive pressures in the pharmaceuticals market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ORIX Corporation

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AZN Q1-2018 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+72.85%

Avg Stock Reaction

-1.24%

Last Quarter Recap

In the last quarter, AstraZeneca reported an impressive EPS of $1.30, beating estimates by over 66%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continue to advance the product pipeline in oncology and respiratory treatments.
Focus on expanding market access for existing drugs.
Commit to maintaining strong research and development investments.

Expectations

Wall Street Expectations

Overall, expectations are mixed as AstraZeneca prepares for its upcoming earnings report. Investors are eager to see if the company can maintain its trend of beating EPS estimates.

Bull Case

If AstraZeneca reports strong earnings and provides positive updates on its product pipeline, it could lead to increased investor confidence and a potential stock price rally.

Bear Case

Conversely, if the company misses expectations or fails to provide clear guidance on future growth, it could lead to a sell-off as investors reassess their positions.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated guidance for EPS and revenue growth for the upcoming quarters?

Clear guidance will help investors understand the company's trajectory and growth potential, influencing stock performance.

How is the product pipeline progressing, especially for key drugs in development?

Updates on the product pipeline can significantly impact future revenue and investor sentiment, making this a critical area of focus.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating AstraZeneca's ability to leverage its strong product pipeline, particularly in oncology, which could lead to higher-than-expected revenue growth.

Supporting Evidence

AstraZeneca has a track record of exceeding EPS estimates, with an 86% beat rate over the last eight quarters.

The options market is pricing a move that aligns with historical averages, suggesting that traders are not fully accounting for potential upside.

Recent product launches have shown strong market acceptance, which could drive revenue higher than anticipated.

Key Risk

If the product pipeline shows significant advancements or unexpected approvals, it could lead to a positive reassessment of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings will be pivotal in determining whether AstraZeneca can sustain its growth momentum in a competitive market.

Bull Confirmed If

AstraZeneca reports EPS growth exceeding 20% year-over-year, indicating strong operational performance.

Bear Confirmed If

A significant decline in EPS or lack of clarity on the product pipeline could signal trouble ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±4.3%

Historical Avg

±4.2%

In line with history

The options market is pricing in a potential move of about 4.3% following the earnings report, indicating that traders expect some volatility.

Options pricing is consistent with the historical average move of the stock around earnings.

Detail

ATM IV

0.3%

30d HV

20.7%

Calls (35K)P/C Ratio: 1.14Puts (91K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AstraZeneca beats expectations, history suggests a potential stock increase of around 1% on the first day, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary from management.

Miss

Should the company miss expectations, history indicates a potential decline of about 1% on the first day, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of key drugs in the pipeline, particularly in oncology.
2Guidance on revenue growth expectations for the upcoming quarters.
3Insights into market share changes in key therapeutic areas.
4Discussion of any challenges faced in the regulatory approval process.
5Management's outlook on competitive pressures in the pharmaceuticals market.